No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
复制标题
DOI：
10.1016/j.jvacx.2019.100029
复制
发表时间：
2019-08-09
期刊：
影响因子：
3.8
通讯作者：
Jul-Larsen, Asne
中科院分区：
文献类型：
--
作者：
Madsen, Anders;Azimi, Linda;Jul-Larsen, Asne
流感是由流感病毒引起的传染性呼吸道疾病。 2009 年甲型 H1N1 流感 (H1N1pdm09) 的大流行爆发为我们提供了研究新型流感疫苗株的体液免疫反应的独特机会。在这里，我们调查了一个人之前接触过不同流感亚型如何影响 2009 年大流行疫苗接种后的体液反应。我们回顾性地选择了 80 名接种疫苗的医护人员 (HCW)，并根据他们的出生年份将其分为 4 组，反映了他们在儿童时期可能首先接触到的流感亚型。分析接种前和接种后21天的血清。我们研究了主要表面蛋白血凝素 (HA) 的抗体，特别是与 HA 蛋白的保守茎结构域结合的抗体。血清学检测用于评估流感特异性抗体的数量和功能，包括病毒中和和参与抗体依赖性细胞介导的细胞毒性 (ADCC) 的自然杀伤 (NK) 细胞的激活。AS03 佐剂的 H1N1pdm09 疫苗在所有医护人员组中引发了强烈的抗体反应。我们发现，抗原经验越丰富的个体，针对 HA 茎结构域的疫苗接种前抗体水平就越高。我们还证明，尽管年轻个体在疫苗接种前的抗体水平较差，但在大流行疫苗接种后，其抗体水平与年长出生群体相似。我们的研究结果对于了解 AS03 佐剂对儿童早期接触不同流感病毒的个体抗体反应的影响非常重要，这对于制定流感疫苗策略至关重要。 (C) 2019 年作者。由爱思唯尔有限公司出版
Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual's previous encounter with different influenza subtypes influences the humoral response after pandemic vaccination in 2009.We retrospectively chose and grouped 80 vaccinated healthcare workers (HCWs) based on their year of birth into 4 groups, reflecting which influenza subtype they were likely first exposed to during childhood. Pre- and 21 days post- vaccination sera were analyzed. We investigated antibodies to the major surface protein hemagglutinin (HA), and specifically antibodies binding to the conserved stalk domain of the HA-protein. Serological assays were used to assess the quantity and functionality of the influenza-specific antibodies, including virus neutralization and activation of natural killer (NK) cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC).The AS03-adjuvanted H1N1pdm09 vaccine elicited robust antibody responses in all groups of HCWs. We found that the more antigenically experienced individuals had higher pre-vaccination antibody-levels towards the stalk domain of the HA. We also demonstrated that despite their inferior pre-vaccination antibody levels, the younger individuals reached similar antibody levels as the older birth-cohorts after pandemic vaccination. Our findings are important for understanding the effect of AS03 adjuvant on the antibody response in individuals exposed to different influenza viruses during their early childhood years, which is crucial for developing vaccine strategies against influenza. (C) 2019 The Authors. Published by Elsevier Ltd.